Encara no tenim significats per a "treat with bortezomib".
1We tested the signature in independent cohorts treated with bortezomib- and lenalidomide-based therapies.
2All patients treated with bortezomib were consecutively registered in the study within 1 year and monitored for emerging BILD.
3No significant differences in toxicity and response rates were seen between patients treated with bortezomib plus steroids and bortezomib alone.
4Grade 3 or 4 adverse events were reported in 75 percent of patients treated with bortezomib and in 60 percent of those treated with dexamethasone.